In Vivo Detection of Human TRPV6-Rich Tumors with Anti-Cancer Peptides Derived from Soricidin |
| |
| Authors: | Chris V Bowen Drew DeBay H Stephen Ewart Pamela Gallant Sean Gormley T Toney Ilenchuk Umar Iqbal Tyler Lutes Marzia Martina Geoffrey Mealing Nadine Merkley Sandra Sperker Maria J Moreno Christopher Rice Raymond T Syvitski John M Stewart |
| |
| Institution: | 1. National Research Council of Canada, Institute for Biodiagnostics (Atlantic) - Neuroimaging Research Laboratory, Halifax, Nova Scotia, Canada.; 2. National Research Council of Canada, Institute for Marine Biosciences, Halifax, Nova Scotia, Canada.; 3. Soricimed Biopharma Inc., Sackville, New Brunswick, Canada.; 4. National Research Council of Canada, Institute of Biological Sciences - Neurobiology Program, Ottawa, Ontario, Canada.; The Chinese University of Hong Kong, Hong Kong, |
| |
| Abstract: | Soricidin is a 54-amino acid peptide found in the paralytic venom of the northern short-tailed shrew (Blarina brevicauda) and has been found to inhibit the transient receptor potential of vallinoid type 6 (TRPV6) calcium channels. We report that two shorter peptides, SOR-C13 and SOR-C27, derived from the C-terminus of soricidin, are high-affinity antagonists of human TRPV6 channels that are up-regulated in a number of cancers. Herein, we report molecular imaging methods that demonstrate the in vivo diagnostic potential of SOR-C13 and SOR-C27 to target tumor sites in mice bearing ovarian or prostate tumors. Our results suggest that these novel peptides may provide an avenue to deliver diagnostic and therapeutic reagents directly to TRPV6-rich tumors and, as such, have potential applications for a range of carcinomas including ovarian, breast, thyroid, prostate and colon, as well as certain leukemia''s and lymphomas. |
| |
| Keywords: | |
|
|
